The Relationship between VDR Gene Polymorphisms Bsm1 and Apa1 with Breast Cancer Risk

Abstract

Background In addition to its multifaceted physiological functions, vitamin D is recognized for its protective role against cancer. To manifest its effects, vitamin D engages with the vitamin D receptor (VDR) gene responsible for its encoding. Investigations have unveiled that polymorphisms within the VDR gene exert influence over the expression and/or functionality of the VDR protein. Notably, certain VDR gene polymorphisms have emerged as particularly pertinent in the context of tumorigenesis, including Fok1 (rs2228570), Bsm1 (rs1544410), Taq1 (rs771236), and Apa1 (rs7975232). This study aims to scrutinize the correlation between the Bsm1 and Apa1 polymorphisms and the susceptibility to breast cancer development.
Materials and Methods In this study, 50 patients suffering from breast cancer with less than 6 months breast cancer diagnosis and 50 healthy control individuals have been chosen. Restriction fragment length polymorphism polymerase chain reaction was used to determine the genotype of polymorphisms.
Results The results of the statistical analysis showed that among the studied polymorphisms, there was no correlation with the development of breast cancer.
Conclusion Studies on various cancers have produced inconsistent results regarding vitamin D's role in the development and progression of cancer. Therefore, further research is necessary to determine vitamin D's role in cancer development and progression.

Keywords

breast cancer / VDR gene / polymorphism

References

[1] Smigal C, Jemal A, Ward E.et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56(03) 168-183

[2] American Cancer Society. Cancer Facts and Figures 2015. Atlanta, GA: American Cancer Society

[3] Czarnecka AM, Klemba A, Krawczyk T.et al. Mitochondrial NADH-dehydrogenase polymorphisms as sporadic breast cancer risk factor. Oncol Rep 2010; 23(02) 531-535

[4] Najm MZ, Zaidi S, Siddiqui WA, Husain SA. Immunohistochemical expression and mutation study of Prohibitin gene in Indian female breast cancer cases. Med Oncol 2013; 30(03) 614

[5] Wacholder S, Hartge P, Prentice R.et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010; 362(11) 986-993

[6] Norman AW. Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr 1998; 67(06) 1108-1110

[7] McCullough ML, Stevens VL, Diver WR.et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case-control study. Breast Cancer Res 2007; 9(01) R9

[8] Tuohimaa P. Vitamin D, aging, and cancer. Nutr Rev 2008; 66(10, suppl 2): S147-S152

[9] Bertone-Johnson ER, Chen WY, Holick MF.et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14(08) 1991-1997

[10] Lowe LC, Guy M, Mansi JL.et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005; 41(08) 1164-1169

[11] Garland CF, Garland FC, Gorham ED.et al. The role of vitamin D in cancer prevention. Am J Public Health 2006; 96(02) 252-261

[12] Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J Bone Miner Res 2007; 22(Suppl. 02) V81-V85

[13] Gorham ED, Garland CF, Garland FC.et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32(03) 210-216

[14] Spina CS, Ton L, Yao M.et al. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 2007; 103(3-5): 757-762

[15] Abbas S, Linseisen J, Slanger T.et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008; 29(01) 93-99

[16] Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 2010; 121(02) 469-477

[17] Touvier M, Chan DS, Lau R.et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20(05) 1003-1016

[18] Fedirko V, Riboli E, Tjønneland A.et al. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol Biomarkers Prev 2012; 21(04) 582-593

[19] Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore) 2013; 92(03) 123-131

[20] James SY, Williams MA, Kelsey SM, Newland AC, Colston KW. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem Pharmacol 1997; 54(05) 625-634

[21] Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108(03) 1083-1086

[22] Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM. The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res 1987; 7(4B): 817-821

[23] Bostick RM, Goodman M, Sidelnikov E. Calcium and vitamin D. In: Potter JD, Lindor NM. eds. Genetics of Colorectal Cancer. New York, NY: Springer Science + Business Media, LCC; 2009: 277-296

[24] Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240(4854): 889-895

[25] Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007; 7(09) 684-700

[26] Zhou H, Xu C, Gu M. Vitamin D receptor (VDR) gene polymorphisms and Graves' disease: a meta-analysis. Clin Endocrinol (Oxf) 2009; 70(06) 938-945

[27] Tokita A, Matsumoto H, Morrison NA.et al. Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women. J Bone Miner Res 1996; 11(07) 1003-1009

[28] Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res 2009; 29(09) 3511-3536

[29] Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009; 30(07) 1170-1180

[30] Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27(23) 3757-3763

[31] Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res 2010; 70(21) 8587-8597

[32] Ingles SA, Haile RW, Henderson BE.et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev 1997; 6(02) 93-98

[33] Dumont P, Leu JI, Della Pietra III AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33(03) 357-365

[34] Hong Y, Miao X, Zhang X.et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 2005; 65(20) 9582-9587

[35] Banerjee P, Chatterjee M. Antiproliferative role of vitamin D and its analogs-a brief overview. Mol Cell Biochem 2003; 253(1-2): 247-254

[36] Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 2005; 16(02) 83-95

[37] Colston KW, Lowe LC, Mansi JL, Campbell MJ. Vitamin D status and breast cancer risk. Anticancer Res 2006; 26(4A): 2573-2580

[38] Mellanby E. Nutrition classics. The Lancet 1:407-12, 1919. An experimental investigation of rickets. Edward Mellanby. Nutr Rev 1976; 34(11) 338-340

[39] Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. Am J Clin Nutr 2008; 88(02) 491S-499S

[40] Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc 2008; 67(02) 115-127

[41] Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 2002; 94(17) 1301-1311

[42] Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 2011; 347(1-2): 55-60

[43] Silvagno F, De Vivo E, Attanasio A, Gallo V, Mazzucco G, Pescarmona G. Mitochondrial localization of vitamin D receptor in human platelets and differentiated megakaryocytes. PLoS One 2010; 5(01) e8670

[44] Zinser GM, Welsh J. Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol 2004; 18(09) 2208-2223

[45] John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res 2005; 65(12) 5470-5479

[46] Engel LS, Orlow I, Sima CS.et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21(10) 1856-1867

[47] Chakraborty A, Mishra AK, Soni A.et al. Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev 2009; 32(5-6): 386-394

[48] Dalessandri KM, Miike R, Wiencke JK.et al. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J Am Coll Surg 2012; 215(05) 652-657

[49] Mishra DK, Wu Y, Sarkissyan M.et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One 2013; 8(03) e57967

[50] Guy M, Lowe LC, Bretherton-Watt D.et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res 2004; 10(16) 5472-5481

[51] Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer 2001; 85(02) 171-175

[52] Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res 1998; 10(01) 43-46

[53] Hou MF, Tien YC, Lin GT.et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002; 74(01) 1-7

[54] Ingles SA, Garcia DG, Wang W.et al. Vitamin D receptor genotype and breast cancer in Latinas (United States). Cancer Causes Control 2000; 11(01) 25-30

RIGHTS & PERMISSIONS

2024 Global Medical Genetics